OnKure Executives Buy Options: A Sign of Confidence Ahead of Key Clinical Milestones
OnKure Therapeutics’ CEO buys 330,000 options, a move that signals executive confidence and aligns incentives with upcoming clinical milestones, hinting at potential upside for investors.
4 minutes to read